臨床醫學研究所

Keyphrases

1. Hepatocellular Carcinoma 100%
2. Taiwan 52%
3. Confidence Interval 32%
4. Hepatitis C Virus 23%
5. Hazard Ratio 23%
6. Mesenchymal Stem Cells 21%
7. Hepatocellular Carcinoma Patients 20%
8. Endothelial Progenitor Cells 18%
9. Cirrhosis 18%
10. Chronic Hepatitis C 17%
11. Hepatitis C 17%
12. Overall Survival 16%
13. Head-and-neck Squamous Cell Carcinoma (HNSCC) 15%
14. Risk Factors 15%
15. Transarterial Chemoembolization 15%
16. Hepatitis B Virus 14%
17. Human Mesenchymal Stem Cells (hMSCs) 14%
18. Migraine 14%
19. Head-and-neck Cancer 14%
20. Reversible Cerebral Vasoconstriction Syndrome 13%
21. Hepatitis B Surface Antigen (HBsAg) 13%
22. Human Immunodeficiency Virus Type 1 (HIV-1) 13%
23. National Cohort Study 13%
24. Clinical Outcomes 13%
25. Chronic Hepatitis B 13%
26. Human Endothelial Progenitor Cells 13%
27. Prognostic Factors 12%
28. Epithelial-mesenchymal Transition 12%
29. Ruptured Abdominal Aortic Aneurysm (rAAA) 12%
30. Taiwanese 12%
31. Multivariate Analysis 11%
32. Albumin-bilirubin Grade 11%
33. Radiofrequency Ablation 10%
34. High Risk 10%
35. Stem Cells 10%
36. Chemotherapy 9%
37. Surgical Resection 9%
38. Direct-acting Antivirals 9%
39. Chronic Kidney Disease 9%
40. Tumor 9%
41. Odds Ratio 9%
42. Sustained Virological Response 8%
43. Chronic Migraine 8%
44. Alpha-fetoprotein 8%
45. Chronic Hepatitis B Patients 8%
46. Hepatitis C Virus Infection 8%
47. Taipei 8%
48. Cardiovascular Events 8%
49. Mesenchymal Stromal Cells 8%
50. Headache 8%
51. Cancer Cells 8%
52. Hepatitis B e Antigen (HBeAg) 8%
53. Oral Tongue Squamous Cell Carcinoma (OTSCC) 7%
54. Macrophages 7%
55. Metastasis 7%
56. Osteogenic Differentiation 7%
57. Barcelona Clinic Liver Cancer 7%
58. Advanced Hepatocellular Carcinoma 7%
59. Immune Checkpoint Inhibitors 7%
60. Angiogenesis 7%
61. Arteriovenous Fistula 7%
62. Coronary Artery Bypass Grafting 7%
63. Gag-Pol 7%
64. Acute Myocardial Infarction 7%
65. Liver 7%
66. Hepatitis B 6%
67. Inflammation 6%
68. Cell Function 6%
69. Hepatocellular Carcinoma Risk 6%
70. Liver Cirrhosis 6%
71. COVID-19 6%
72. Propensity Score Analysis 6%
73. Cirrhotic Patients 6%
74. Neovascularization 6%
75. Ischemic Stroke 6%
76. All-cause Mortality 6%
77. Major Adverse Cardiovascular Events 6%
78. Percutaneous Coronary Intervention 6%
79. Oxidative Stress 6%
80. MELD Score 6%
81. Virus 6%
82. Meta-analysis 6%
83. Coronary Artery Disease 6%
84. Performance Status 6%
85. Ischemia 6%
86. Cox Proportional Hazards Model 5%
87. Treatment Outcome 5%
88. Overexpression 5%
89. Unresectable Hepatocellular Carcinoma 5%
90. Computed Tomography 5%
91. Tumor Recurrence 5%
92. Adjusted Hazard Ratio 5%
93. Hemodialysis Patients 5%
94. Non-diabetic 5%
95. Tumor Necrosis Factor-α 5%
96. Serum Levels 5%
97. AIDS/HIV 5%
98. Antiretroviral Therapy 5%
99. Patients with Coronary Artery Disease 5%
100. Cardiovascular Disease 5%

Medicine and Dentistry

1. Hepatocellular Carcinoma 97%
2. Neoplasm 23%
3. Liver Cirrhosis 19%
4. Hazard Ratio 18%
5. Surgery 17%
6. Mesenchymal Stem Cell 17%
7. Hepatitis B Virus 17%
8. Hepatitis C Virus 16%
9. Overall Survival 16%
10. Transcatheter Arterial Chemoembolization 15%
11. Endothelial Progenitor Cell 15%
12. Cardiovascular System 15%
13. Diseases 14%
14. Coronary Artery Disease 14%
15. Chronic Hepatitis C 13%
16. Bilirubin 12%
17. Chronic Hepatitis B 12%
18. Cohort Analysis 11%
19. Hepatitis C 11%
20. Malignant Neoplasm 11%
21. Prevalence 10%
22. Proportional Hazards Model 9%
23. Infection 9%
24. Diabetes Mellitus 9%
25. Migraine 9%
26. Liver Cancer 9%
27. Chronic Kidney Disease 9%
28. Hemodialysis 9%
29. Radiofrequency Ablation 8%
30. Head and Neck Squamous Cell Carcinoma 8%
31. Prognostic Factor 8%
32. Multivariate Analysis 8%
33. Aortic Dissection 8%
34. Headache 8%
35. Hepatitis B 8%
36. Metastatic Carcinoma 8%
37. In Vitro 8%
38. Odds Ratio 7%
39. Abdominal Aortic Aneurysm 7%
40. Arteriovenous Fistula 7%
41. Recurrent Disease 7%
42. Cancer Staging 7%
43. Cardiovascular Disease 7%
44. Platelet 7%
45. Endovascular Aneurysm Repair 7%
46. Antiviral Therapy 6%
47. Cancer 6%
48. Survival Rate 6%
49. Head and Neck Cancer 6%
50. Reversible Cerebral Vasoconstriction Syndrome 6%
51. Coronary Artery Bypass Graft 6%
52. Fibrosis 6%
53. Stem Cell 6%
54. Biological Marker 6%
55. Computer Assisted Tomography 6%
56. Acute Kidney Injury 6%
57. Percutaneous Coronary Intervention 6%
58. Stent-Graft 5%
59. Kidney Function 5%
60. Immune Checkpoint Inhibitor 5%
61. Angiogenesis 5%
62. Apoplexy 5%
63. Squamous Cell Carcinoma 5%
64. Antiviral Drug 5%
65. Nonalcoholic Fatty Liver 5%
66. Mouth Squamous Cell Carcinoma 5%